Shares of Molbio Diagnostics Ltd on Monday listed with a premium of over 21% against the issue price of ₹807.
The stock started trading at ₹980, registering a jump of 21.43% on the BSE. It further surged 24.16% to ₹1,002.05.
At the NSE also, the stock made its market debut at ₹980.
1 August 2026
Get the latest issue of Outlook Business
The company commanded a market valuation of ₹10,875.77 crore.
Molbio Diagnostics' initial public offering received 70.26 times subscription on the final day of bidding on Wednesday last week.
The ₹940-crore IPO had a price band of ₹768-807 per share.
The Goa-based company's IPO had a fresh issue of shares, worth up to ₹200 crore, and an offer-for-sale (OFS) of up to 91.66 lakh equity shares by existing shareholders.
The company proposes to utilise ₹106 crore from the fresh issue proceeds towards capital expenditure for setting up infrastructure for an R&D facility, Centre of Excellence and connected office space.
Another ₹72 crore will be deployed towards the purchase of plant, machinery and other equipment for its Goa Unit I, Goa Unit II and Visakhapatnam unit, while the remaining funds will be used for general corporate purposes.
Incorporated in 2000, Molbio Diagnostics is a point-of-care diagnostics company offering molecular testing for 30 diseases, including tuberculosis, COVID, HIV, HPV and Hepatitis B and C.
Its 'Truenat' platform, patented in more than 100 countries for diagnosis of multiple infectious and non-communicable diseases, is a point-of-care polymerase chain reaction (PCR) platform. The battery-operated platform can be deployed in resource-limited settings and facilitates decentralised diagnosis within an hour.
